- Home
- BDTX vs AGEN Comparison
BDTX vs AGEN Comparison
Compare BDTX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- AGEN
- Stock Information
- Founded
- BDTX 2014
- AGEN 1994
- Country
- BDTX United States
- AGEN United States
- Employees
- BDTX N/A
- AGEN N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BDTX Health Care
- AGEN Health Care
- Exchange
- BDTX Nasdaq
- AGEN Nasdaq
- Market Cap
- BDTX 323.2M
- AGEN 97.7M
- IPO Year
- BDTX 2020
- AGEN 2000
- Fundamental
- Price
- BDTX $3.21
- AGEN $4.50
- Analyst Decision
- BDTX Strong Buy
- AGEN Buy
- Analyst Count
- BDTX 4
- AGEN 3
- Target Price
- BDTX $15.50
- AGEN $10.00
- AVG Volume (30 Days)
- BDTX 1.0M
- AGEN 346.0K
- Earning Date
- BDTX 11-04-2024
- AGEN 11-05-2024
- Dividend Yield
- BDTX N/A
- AGEN N/A
- EPS Growth
- BDTX N/A
- AGEN N/A
- EPS
- BDTX N/A
- AGEN N/A
- Revenue
- BDTX N/A
- AGEN $159,630,000.00
- Revenue This Year
- BDTX N/A
- AGEN N/A
- Revenue Next Year
- BDTX N/A
- AGEN $0.04
- P/E Ratio
- BDTX N/A
- AGEN N/A
- Revenue Growth
- BDTX N/A
- AGEN 60.67
- 52 Week Low
- BDTX $1.62
- AGEN $4.18
- 52 Week High
- BDTX $7.66
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- BDTX 29.72
- AGEN 40.31
- Support Level
- BDTX $3.13
- AGEN $4.50
- Resistance Level
- BDTX $3.42
- AGEN $4.78
- Average True Range (ATR)
- BDTX 0.25
- AGEN 0.29
- MACD
- BDTX 0.01
- AGEN 0.02
- Stochastic Oscillator
- BDTX 7.95
- AGEN 30.77
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).